Quantcast

Latest CryoLife Inc. Stories

2014-07-24 08:34:06

ATLANTA, July 24, 2014 /PRNewswire/ -- Second Quarter and Recent Highlights: -- Appointed Pat Mackin as President and Chief Executive Officer effective September 2, 2014 -- Product revenues grew 12 percent year-over-year to $20.4 million -- BioGlue(®) revenues grew 14 percent year-over-year to $15.3 million -- PerClot(®) revenues grew 22 percent year-over-year to $1.1 million -- HeRO(®) Graft revenues grew 20 percent year-over-year to $1.7 million --...

2014-07-15 08:29:00

ATLANTA, July 15, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2014 second quarter financial results will be released on Thursday, July 24, 2014. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief...

2014-07-10 08:27:37

ATLANTA, July 10, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has appointed James Patrick (Pat) Mackin, age 47, as President and Chief Executive Officer, effective September 2, 2014. Mr. Mackin is expected to be appointed to the Company's Board of Directors after his employment begins....

2014-05-22 16:27:36

ATLANTA, May 22, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a nine percent increase in the quarterly cash dividend for the second quarter 2014 from $0.0275 to $0.03 per share of common stock outstanding. At the new rate, the indicated dividend on an annual basis is $0.12 per share compared to the previous rate of $0.11 per...

2014-04-29 08:36:19

ATLANTA, April 29, 2014 /PRNewswire/ -- First Quarter Highlights: -- Grew HeRO(®) Graft revenues 26 percent year-over-year to $1.6 million -- Received FDA approval to begin PerClot(®) clinical trial -- Received FDA 510(k) clearance for PerClot Topical -- Secured distribution rights and purchase option for ProCol(®) Vascular Bioprosthesis -- Established new regional headquarters in Singapore to expand presence in rapidly growing Asia-Pacific...

2014-04-29 08:36:10

Requests Court Confirmation that PerClot Does Not Infringe Bard Patent ATLANTA, April 29, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has received 510(k) clearance for PerClot Topical hemostatic powder from the U.S. Food and Drug Administration (FDA). This clearance allows CryoLife to begin commercialization of PerClot Topical hemostatic powder in the U.S....

2014-04-15 08:30:34

ATLANTA, April 15, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2014 first quarter financial results will be released on Tuesday, April 29, 2014. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief...

2014-04-02 08:33:56

ATLANTA, April 2, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has received approval of its Investigational Device Exemption (IDE) for PerClot from the United States Food and Drug Administration (FDA). This approval allows CryoLife to begin its pivotal clinical trial to gain approval to commercialize PerClot in the U.S. The Company plans to begin enrollment in...

2014-03-27 08:34:44

Provides access for dialysis patients; complementary to HeRO® Graft ATLANTA, March 27, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has acquired the exclusive worldwide distribution rights for the ProCol Vascular Bioprosthesis ("ProCol") from Hancock Jaffe Laboratories, Inc. In addition, beginning 24 months after execution of the agreement, CryoLife has the right to...

2014-03-19 08:29:42

ATLANTA, March 19, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will host its third Central Venous Pathology (CVP) Summit on March 25-27, 2014 at CryoLife's training facility at its corporate headquarters in suburban Atlanta. The Company expects that over 80 physicians and dialysis therapy professionals will attend the CVP Summit. The CVP Summit will be led by...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related